Applications of apatinib in preparation of drugs for preventing and treating radiation induced brain injury

Abstract

The invention discloses applications of apatinib in preparation of drugs for preventing and treating radiation induced brain injury. Referring to international examples of exploring new drug indications, apatinib treatment and observation on 2 radiation brain injury cases without intracranial metastases are carried out, results show that, after one month of 250 mg qd apatinib treatment, the cerebral edema of the two patients are notably shrunk after irradiation, and the headache symptoms in one of the patients are significantly relieved. Stage II clinical research of apatinib mesylate on radiation encephalopathy treatment can be further performed; the curative effects of the apatinib can be explored, and safety assessment can be carried out; and the results show that the apatinib can reduce the lesion areas of the patients, improve cerebral necrosis and lower LENT / SOMA scores; drugs can be well tolerated; and the adverse reaction of the patients are mainly grade 1-2, and drug related death events are not observed. The applications of the apatinib are expanded; and a novel drug for treating radiation induced brain injury is also developed.

Description

technical field [0001] The invention belongs to the technical field of medicine, relates to a new application of Apatinib, in particular to the application of Apatinib or a pharmaceutically acceptable salt thereof in the preparation of a medicine for preventing and treating radiation-induced brain injury. Background technique [0002] The clinical manifestations of radiation encephalopathy are mainly localized symptoms or signs caused by increased intracranial pressure caused by cerebral edema and necrotic brain tissue. The current main treatment options for radiation-induced brain injury include: immunosuppressants such as glucocorticoids and anti-angiogenic drug Bevacizumab, and adjuvant drugs such as dehydration (mannitol), free radical scavengers ( edaravone) and gangliosides. [0003] At present, it is reported in the literature that the effective rate of traditional hormone-based treatment schemes is only about 20%-35%, and hormones can improve cerebral edema while ...

AI Technical Summary

Problems solved by technology

[0003] At present, it is reported in the literature that the effective rate of traditional hormone-based treatment schemes is only about 20%-35%, and hormones can improve cerebral edema while causing serious side effects such as gastrointestinal bleeding and osteoporosis, while bevacizumab Although the effective rate of treatment is significantly higher than that of hormones, it is expensive and difficult to maintain for a long time in clinical application. At the same time, there is a problem of easy recurrence after drug withdrawal, so repeated hospitalization is required

Images